Jim Simons’s Elicio Therapeutics ELTX Stock Holding History

Jim Simons’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.3M	Buy	121,631 +93,520	+333%	+$903K	﹤0.01%	2131
2025 Q4	$224K	Sell	28,111 -20,560	-42%	-$187K	﹤0.01%	2859
2025 Q3	$532K	Buy	+48,671	New	+$493K	﹤0.01%	2762
2024 Q2	–	Sell	-11,761	Closed	-$89K	–	3601
2024 Q1	$89K	Sell	11,761 -4,705	-29%	-$23.6K	﹤0.01%	3394
2023 Q4	$137K	Buy	+16,466	New	+$107K	﹤0.01%	3230
2023 Q2	–	Sell	-9,302	Closed	-$54K	–	4014
2023 Q1	$54K	Sell	9,302 -2,868	-24%	-$19.1K	﹤0.01%	3643
2022 Q4	$99K	Sell	12,170 -8,728	-42%	-$79.3K	﹤0.01%	3619
2022 Q3	$192K	Sell	20,898 -452	-2%	-$4.72K	﹤0.01%	3399
2022 Q2	$243K	Sell	21,350 -1,020	-5%	-$16.3K	﹤0.01%	3562
2022 Q1	$474K	Buy	22,370 +3,260	+17%	+$73.6K	﹤0.01%	3230
2021 Q4	$554K	Buy	+19,110	New	+$966K	﹤0.01%	3027

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jim Simons's ELTX Position: Q1 2026 in Review

Jim Simons increased its Elicio Therapeutics (ELTX) stake by 333% in Q1 2026, buying an estimated $903K and bringing the position to 121,631 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2131.

Jim Simons first reported a position in ELTX in Q4 2021 and has held it in 11 quarters since. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

Jim Simons held 121,631 shares of Elicio Therapeutics worth $1.3M as of Q1 2026.
Jim Simons bought 93,520 Elicio Therapeutics shares in Q1 2026, an estimated $903K.
Elicio Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2131 holding.
Jim Simons first reported a position in Elicio Therapeutics in Q4 2021 and has held it in 11 quarters since.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.